Irinquiries@prestigebrands.com
Prestige Consumer Healthcare Inc.
660 White Plains Road – Ste 250
Tarrytown, NY 10591
Telephone: 914-524-6819
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of
Report (Date of earliest event reported): October 11,
2007
PRESTIGE
BRANDS HOLDINGS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
001-32433
|
20-1297589
|
|
(State
or other jurisdiction
|
(Commission
File Number)
|
(IRS
Employer
|
|
of
incorporation)
|
Identification
No.)
|
&
#160;
90
North Broadway, Irvington, New York 10533
(Address
of principal executive offices, including Zip Code)
(914)
524-6810
(Registrant’s
telephone number, including area code)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
Item
7.01. Regulation FD Disclosure.
On
October 11, 2007, Prestige Brands Holdings, Inc. (the ‘‘Registrant’’) issued a
press release in which it announced that it would join other providers of
Over-the-Counter Oral Infant Cough and Cold medicated products by voluntarily
recalling two of its Little Colds® products. A copy of the press
release is attached hereto as Exhibit 99.1 and incorporated herein by
reference.
The
information in this Form 8-K and Exhibit 99.1 attached hereto shall not be
deemed to be ‘‘filed’’ for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended, or otherwise subject to the liabilities of that section,
unless the Registrant specifically states that the information is to be
considered “filed” under the Securities Exchange Act of 1934 or incorporates it
by reference into a filing under the Securities Act of 1933, as amended,
or the
Securities Exchange Act of 1934.
Item
9.01 Financial Statements and Exhibits.
|
(d)
|
Exhibits.
|
|
Exhibit
|
Description
|
|
99.1
|
Press
Release dated
October
11, 2007
(furnished
only).
|
SIGNATURES
Pursuant
to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report
to
be signed on its behalf by the undersigned hereunto duly
authorized.
| Date: October 11, 2007 | PRESTIGE BRANDS HOLDINGS, INC. | ||
| By: | /s/ Charles N. Jolly | ||
| Name: Charles N. Jolly | |||
| Title: General Counsel and Secretary | |||
EXHIBIT
INDEX
| Exhibit | Description |
| 99.1 | Press Release dated October 11, 2007 (furnished only). |
Exhibit
99.1
Prestige
Brands Holdings, Inc. Joins Makers of OTC Oral Infant Cough and Cold Medicated
Products in Voluntary Withdrawal of Two Little Colds®
Products
Parents
Can Turn To Non-Medicated Alternatives from Little
Remedies®
Irvington,
NY, October 11, 2007—Prestige Brands Holdings, Inc (NYSE-PBH) today announced a
voluntary market withdrawal of its two medicated over-the-counter infant oral
cough and cold products as part of an industry-wide effort to improve labeling
and encourage proper use of these products in children. The move by Prestige
and
the entire industry is a cautionary step to address reports of misuse of oral
cough and cold products in infants. Industry recommendations on permanent
actions have been submitted to the Food and Drug Administration in preparation
for an upcoming joint Advisory Committee meeting on October 18-19th.
Little
Colds® Decongestant Plus Cough and Little Colds® Multi-Symptom Cold Formula will
be voluntarily withdrawn from the market. These products are and will continue
to be safe and effective when taken as directed, and have been used by parents
for decades to help relieve their children’s cold symptoms.
The
two
Little Colds® products being voluntarily withdrawn represent approximately 1% of
the Company’s net sales. They are part of the Little Remedies® line of pediatric
over-the-counter healthcare products, a pioneer in children’s products specially
formulated without dyes, alcohol or saccharin. These two items and the entire
Little Remedies® line have an excellent record of safe use.
Little
Remedies® Alternatives Available
Parents
seeking alternative treatments to medicated cough and cold products for their
young children should look to the Little Remedies® non-medicated products for
cough and cold symptoms. These include Little Noses® Saline Spray Drops for
relief of dry or stuffy noses, Little Noses® Stuffy Nose Kit which contains
saline spray/drops and a nasal aspirator, and Little Colds® Baby Rub Soothing
Ointment, an externally applied ointment which is comforting and
soothing.
Consumers
seeking additional information on the Little Colds® voluntary withdrawal or on
the line of Little Remedies® non-medicated products for coughs and colds may
contact the Consumer Affairs Department of Prestige Brands at 1-800-7-LITTLE
(1-800-754-8853).
Located
in Irvington, New York, Prestige Brands Holdings, Inc. is a marketer and
distributor of brand name over-the-counter health care, personal care and
household cleaning products sold throughout the U.S., Canada, and in
certain international markets. Key brands include Compound W(R) wart remover,
Chloraseptic(R) sore throat treatment, New-Skin(R) liquid bandage, Clear Eyes(R)
and Murine(R) eye care products, Little Remedies(R) pediatric over-the-counter
products, The Doctor's (R) Night Guard(TM) dental protector, Cutex(R) nail
polish remover, Comet(R) and Spic and Span(R) household cleaners, and other
well-known brands.